|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang Y and Zhou BP: Epithelial-mesenchymal
transition in breast cancer progression and metastasis. Chin J
Cancer. 30:603–611. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
van Zijl F, Krupitza G and Mikulits W:
Initial steps of metastasis: Cell invasion and endothelial
transmigration. Mutat Res. 728:23–34. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chambers AF, Groom AC and MacDonald IC:
Dissemination and growth of cancer cells in metastatic sites. Nat
Rev Cancer. 2:563–572. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Abak A, Amini S, Sakhinia E and Abhari A:
MicroRNA-221: Biogenesis, function and signatures in human cancers.
Eur Rev Med Pharmacol Sci. 22:3094–3117. 2018.PubMed/NCBI
|
|
7
|
Ardekani AM and Naeini MM: The Role of
MicroRNAs in human diseases. Avicenna J Med Biotechnol. 2:161–179.
2010.PubMed/NCBI
|
|
8
|
Ullah S, John P and Bhatti A: MicroRNAs
with a role in gene regulation and in human diseases. Mol Biol Rep.
41:225–232. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tüfekci KU, Oner MG, Meuwissen RL and Genc
S: The role of microRNAs in human diseases. Methods Mol Biol.
1107:33–50. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Waldman SA and Terzic A: Applications of
microRNA in cancer: Exploring the advantages of miRNA. Clin Transl
Sci. 2:248–249. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Reddy KB: MicroRNA (miRNA) in cancer.
Cancer Cell Int. 15:382015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee YS and Dutta A: MicroRNAs in cancer.
Annu Rev Pathol. 4:199–227. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen L, Li Y, Fu Y, Peng J, Mo MH,
Stamatakos M, Teal CB, Brem RF, Stojadinovic A, Grinkemeyer M, et
al: Role of deregulated microRNAs in breast cancer progression
using FFPE tissue. PLoS One. 8:e542132013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang B, Li J, Sun M, Sun L and Zhang X:
miRNA expression in breast cancer varies with lymph node metastasis
and other clinicopathologic features. IUBMB Life. 66:371–377. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tang J, Ahmad A and Sarkar FH: The role of
microRNAs in breast cancer migration, invasion and metastasis. Int
J Mol Sci. 13:13414–13437. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
van Schooneveld E, Wildiers H, Vergote I,
Vermeulen PB, Dirix LY and Van Laere SJ: Dysregulation of microRNAs
in breast cancer and their potential role as prognostic and
predictive biomarkers in patient management. Breast Cancer Res.
17:212015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ng L, Wan TM, Man JH, Chow AK, Iyer D,
Chen G, Yau TC, Lo OS, Foo DC, Poon JT, et al: Identification of
serum miR-139-3p as a non-invasive biomarker for colorectal cancer.
Oncotarget. 8:27393–27400. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu X, Duan B, Dong Y, He C, Zhou H, Sheng
H, Gao H and Zhang X: MicroRNA-139-3p indicates a poor prognosis of
colon cancer. Int J Clin Exp Pathol. 7:8046–8052. 2014.PubMed/NCBI
|
|
19
|
Yonemori M, Seki N, Yoshino H, Matsushita
R, Miyamoto K, Nakagawa M and Enokida H: Dual tumor-suppressors
miR-139-5p and miR-139-3p targeting matrix metalloprotease 11 in
bladder cancer. Cancer Sci. 107:1233–1242. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee JA, Lee HY, Lee ES, Kim I and Bae JW:
Prognostic implications of MicroRNA-21 overexpression in invasive
ductal carcinomas of the breast. J Breast Cancer. 14:269–275. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhai J, Yang X, Zhang Y, Qi Q, Hu J and
Wang Q: Reduced expression levels of the death-associated protein
kinase and E-cadherin are correlated with the development of
esophageal squamous cell carcinoma. Exp Ther Med. 5:972–976. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lánczky A, Nagy Á, Bottai G, Munkácsy G,
Szabó A, Santarpia L and Győrffy B: miRpower: A web-tool to
validate survival-associated miRNAs utilizing expression data from
2178 breast cancer patients. Breast Cancer Res Treat. 160:439–446.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dongre A, Rashidian M, Reinhardt F,
Bagnato A, Keckesova Z, Ploegh HL and Weinberg RA:
Epithelial-to-mesenchymal transition contributes to
immunosuppression in breast carcinomas. Cancer Res. 77:3982–3989.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bill R and Christofori G: The relevance of
EMT in breast cancer metastasis: Correlation or causality. FEBS
Lett. 589:1577–1587. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sannigrahi MK, Sharma R, Singh V, Panda
NK, Rattan V and Khullar M: Role of host miRNA Hsa-miR-139-3p in
HPV-16-induced carcinomas. Clin Cancer Res. 23:3884–3895. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang P, Xi J and Liu S: miR-139-3p
induces cell apoptosis and inhibits metastasis of cervical cancer
by targeting NOB1. Biomed Pharmacother. 83:850–856. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jin M, Saucan L, Farquhar MG and Palade
GE: Rab1a and multiple other Rab proteins are associated with the
transcytotic pathway in rat liver. J Biol Chem. 271:30105–30113.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tanaka M, Mun S, Harada A, Ohkawa Y,
Inagaki A, Sano S, Takahashi K, Izumi Y, Osada-Oka M, Wanibuchi H,
et al: Hsc70 contributes to cancer cell survival by preventing
Rab1A degradation under stress conditions. PLoS One. 9:e967852014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Thomas JD, Zhang YJ, Wei YH, Cho JH,
Morris LE, Wang HY and Zheng XFS: Rab1A is an mTORC1 activator and
a colorectal oncogene. Cancer Cell. 30:181–182. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang X, Liu F, Qin X, Huang T, Huang B,
Zhang Y and Jiang B: Expression of Rab1A is upregulated in human
lung cancer and associated with tumor size and T stage. Aging
(Albany NY). 8:2790–2798. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xu H, Qian M, Zhao B, Wu C, Maskey N, Song
H, Li D, Song J, Hua K and Fang L: Inhibition of RAB1A suppresses
epithelial-mesenchymal transition and proliferation of
triple-negative breast cancer cells. Oncol Rep. 37:1619–1626. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shimada K, Uzawa K, Kato M, Endo Y, Shiiba
M, Bukawa H, Yokoe H, Seki N and Tanzawa H: Aberrant expression of
RAB1A in human tongue cancer. Br J Cancer. 92:1915–1921. 2005.
View Article : Google Scholar : PubMed/NCBI
|
